A comparative study of European rare disease and orphan drug markets
- 31 October 2010
- journal article
- research article
- Published by Elsevier BV in Health Policy
- Vol. 97 (2-3), 173-179
- https://doi.org/10.1016/j.healthpol.2010.05.017
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Pharmaceutical Risk-Sharing AgreementsPharmacoEconomics, 2008
- Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policyCMAJ : Canadian Medical Association Journal, 2006
- National Institute for Clinical Excellence and its value judgmentsBMJ, 2004